SEMA4B and gastric cancer: Li et al found that a panel of 3 mRNAs (SPINK7, PPL, and SEMA4B) and 2 microRNAs (MIR140-5p and MIR301a) can discriminate GC patients from healthy controls with credible clinical performance.[7] Using a multiple logistic model, Li et al maximized the sensitivity and specificity to be 75% and 83%.